Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains

Steven Rubin1, Jeremy Mauldin, Konstantin Chumakov

  • 1Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA. rubins@cber.fda.gov

Vaccine
|November 29, 2005
PubMed

Insights

Mumps virus may not be monotypic, challenging vaccine assumptions. While most sera neutralize both tested strains, low antibody levels may increase breakthrough infection risk.

Area of Science:

  • Virology
  • Immunology
  • Epidemiology

Background:

  • Mumps virus resurgence despite vaccination raises questions about its serological monotypy.
  • Evidence suggests antigenic diversity among mumps virus strains, challenging long-held assumptions.

Purpose of the Study:

  • To investigate potential mumps virus serotypes by selecting distinct strains.
  • To assess the cross-neutralization capabilities of human sera against different mumps virus strains.

Main Methods:

  • Phylogenetic analysis of the hemagglutinin-neuraminidase (HN) protein to select representative mumps virus strains (Enders and Lo1).
  • Evaluation of human serum neutralization titers against both selected strains.

Main Results:

  • 90% of sera neutralizing one strain also neutralized the other, indicating significant cross-neutralization.
  • Significant differences in neutralization titers between strains suggest inter-strain antigenic variability.
  • Low neutralization titers (1:8) were associated with inability to co-neutralize, potentially explaining breakthrough infections.

Conclusions:

  • Mumps virus is likely not serologically diverse, arguing against multiple serotypes.
  • Low neutralizing antibody levels may predispose individuals to breakthrough mumps infections.
  • Findings offer an explanation for mumps cases in vaccinated or previously infected individuals.